Dupixent (dupilumab) was the first biologic treatment approved for atopic dermatitis. It became available in 2017. It is currently approved for adults and adolescents 6 months and older with ...

Solid sales of Dupixent (approved for use in certain patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis and eosinophilic esophagitis) have fueled the top line for ...

Analysts predict peak annual sales of around $2.5 billion for Dupixent, which the FDA approved in March last year for eczema – known medically as moderate-to-severe atopic dermatitis – after ...

According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent ...

Over the next 10 years, GlobalData has predicted that Dupixent will remain the most prescribed biologic therapy for atopic dermatitis, with global sales of $5.3 billion in 2027.

‘The #atopic_dermatitis market is heating up! #Sanofi is gearing up to challenge #Dupixent's dominance. What new treatments are on the horizon?’ Sanofi is also advancing in the AD arena with ...

including atopic dermatitis (AD), in which it is considered the gold standard, says GlobalData, a data and analytics company. “Having Dupixent as the gold standard for AD, Sanofi has set a high ...

Shares of Regeneron Pharmaceuticals, Inc. REGN have dropped 35.6% in the ... sales of Dupixent. Solid sales of Dupixent (approved for use in certain patients with atopic dermatitis, asthma ...